SCHEMBL31363878

SCHEMBL31363878

CC1=CN(C)CC(C)=C1NC(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.36
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
LIPE Q05469 1/20 0.33
NAMPT P43490 2/20 0.33
MAPKAPK2 P49137 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA9 Q16790 1/20 0.33
CD274 Q9NZQ7 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
CYP17A1 P05093 1/20 0.32
ATR Q13535 1/20 0.32
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
PTPN6 P29350 1/20 0.32
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16166641 0.65 DRD2 (0.38) DRD2GSK3BDYRK1ANFKB1NFKB2
SCHEMBL21206288 0.64 NFKB1 (0.35) DRD2NFKB1NFKB2RELALIPE
SCHEMBL31363590 0.64 DRD2 (0.33) DRD2GSK3BDYRK1ANFKB1NFKB2
SCHEMBL13055402 0.62 CYP17A1 (0.59) DRD2LIPENAMPTMAPKAPK2CA12
SCHEMBL1656241 0.62 NFKB1 (0.41) DRD2NFKB1NFKB2RELACA1
SCHEMBL27346938 0.62 NFKB1 (0.36) DRD2GSK3BDYRK1ANFKB1NFKB2
SCHEMBL3305574 0.62 LIPE (0.36) DRD2NFKB1NFKB2RELALIPE
SCHEMBL17844767 0.62 KMT2A (0.49) GSK3BDYRK1ANAMPTCYP17A1ATR
SCHEMBL35210874 0.62 SMN1; SMN2 (0.57) GSK3BDYRK1ACA12CA1CA9
SCHEMBL219325 0.62 CYP17A1 (0.39) DRD2GSK3BDYRK1ALIPENAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059074-A1 BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2025-03-20 WO disclosed